The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
New data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year…
Source: financialpost.com